文献速递自身炎症与 IgG4 相关病

2021年EULAR/美国风湿病学会关于白介素-1介导自身炎症性疾病诊断、管理和监测的考虑要点:冷吡啉相关周期性综合征、肿瘤坏死因子受体相关周期性综合征、甲羟戊酸激酶缺乏症和白介素-1受体拮抗剂缺乏症

The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
PubMed 文献 · Arthritis Rheumatol · 2022-05-27

该文件为2021年EULAR/美国风湿病学会发布的考虑要点,针对白介素-1介导的自身炎症性疾病(CAPS、TRAPS、MKD、DIRA),通过系统文献综述和专家共识(Delphi调查)制定。工作组制定了5条总体原则、14条诊断相关声明、10条治疗声明和9条长期监测声明,并提出了疾病特异性监测炎症所致器官损伤进展的框架及报告的治疗。

要点

  • 制定5条总体原则、14条诊断声明、10条治疗声明和9条长期监测声明。
  • 推荐基于证据和/或共识,用于CAPS、TRAPS、MKD和DIRA患者的诊断、治疗和监测。
  • 提出了疾病特异性监测炎症诱导器官损伤进展的框架并报告了相关治疗。

核心结论

  • 2021年EULAR/美国风湿病学会考虑要点代表基于已发表数据和专家意见的最新知识,用于指导CAPS、TRAPS、MKD和DIRA患者的诊断评估、治疗和监测,并标准化和改善护理、生活质量和疾病结局。

研究设计与样本

  • 建立了由医师专家(包括风湿病学家)、患者或照护者及联合医疗专业人员组成的多国多学科工作组。
  • 进行了证据合成,包括系统文献综述和通过调查的专家共识(Delphi)。
  • 采用共识方法制定并投票声明以指导最佳患者护理。

主要发现

  • 工作组制定了5条总体原则、14条诊断相关声明、10条治疗声明和9条聚焦长期监测的声明,这些声明基于证据和/或共识。
  • 制定了针对炎症诱导器官损伤进展的疾病特异性监测框架,并报告了CAPS、TRAPS、MKD和DIRA的治疗。

关键数值与推荐

  • 制定了5条总体原则、14条诊断声明、10条治疗声明和9条长期监测声明。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases, including the cryopyrin- associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD) and deficiency of the IL-1 receptor antagonist (DIRA), belong to a group of rare immunodysregulatory diseases that primarily present in early childhood with variable multiorgan involvement. When untreated, patients with severe clinical phenotypes have a poor prognosis, and diagnosis and management of these patients can be challenging. However, approved treatments targeting the proinflammatory cytokine IL-1 have been life changing and have significantly improved patient outcomes. OBJECTIVE: To establish evidence-based recommendations for diagnosis, treatment and monitoring of patients with IL-1 mediated autoinflammatory diseases to standardise their management. METHODS: A multinational, multidisciplinary task force consisting of physician experts, including rheumatologists, patients or caregivers and allied healthcare professionals, was established. Evidence synthesis, including systematic literature review and expert consensus (Delphi) via surveys, was conducted. Consensus methodology was used to formulate and vote on statements to guide optimal patient care. RESULTS: The task force devised five overarching principles, 14 statements related to diagnosis, 10 on therapy, and nine focused on long-term monitoring that were evidence and/or consensus-based for patients with IL-1 mediated diseases. An outline was developed for disease-specific monitoring of inflammation-induced organ damage progression and reported treatments of CAPS, TRAPS, MKD and DIRA. CONCLUSION: The 2021 EULAR/American College of Rheumatology points to consider represent state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitoring of patients with CAPS, TRAPS, MKD and DIRA, and to standardise and improve care, quality of life and disease outcomes.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. Arthritis Rheumatol. 2022. PMID: 35621220. doi:10.1002/art.42139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。